- Home
- STTK vs TWIN Comparison
STTK vs TWIN Comparison
Compare STTK & TWIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- TWIN
- Stock Information
- Founded
- STTK 2016
- TWIN 1918
- Country
- STTK United States
- TWIN United States
- Employees
- STTK N/A
- TWIN N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- TWIN Industrial Machinery/Components
- Sector
- STTK Health Care
- TWIN Industrials
- Exchange
- STTK Nasdaq
- TWIN Nasdaq
- Market Cap
- STTK 37.6M
- TWIN 97.0M
- IPO Year
- STTK 2020
- TWIN N/A
- Fundamental
- Price
- STTK $0.83
- TWIN $9.41
- Analyst Decision
- STTK Hold
- TWIN Strong Buy
- Analyst Count
- STTK 4
- TWIN 1
- Target Price
- STTK $3.00
- TWIN $12.00
- AVG Volume (30 Days)
- STTK 480.9K
- TWIN 154.7K
- Earning Date
- STTK 07-31-2025
- TWIN 08-14-2025
- Dividend Yield
- STTK N/A
- TWIN 1.69%
- EPS Growth
- STTK N/A
- TWIN N/A
- EPS
- STTK N/A
- TWIN 0.29
- Revenue
- STTK $4,606,000.00
- TWIN $328,478,000.00
- Revenue This Year
- STTK N/A
- TWIN $27.91
- Revenue Next Year
- STTK N/A
- TWIN N/A
- P/E Ratio
- STTK N/A
- TWIN $32.20
- Revenue Growth
- STTK 69.65
- TWIN 11.49
- 52 Week Low
- STTK $0.69
- TWIN $6.16
- 52 Week High
- STTK $4.99
- TWIN $14.98
- Technical
- Relative Strength Index (RSI)
- STTK 38.86
- TWIN 62.89
- Support Level
- STTK $0.75
- TWIN $9.19
- Resistance Level
- STTK $0.85
- TWIN $9.77
- Average True Range (ATR)
- STTK 0.09
- TWIN 0.51
- MACD
- STTK -0.01
- TWIN 0.02
- Stochastic Oscillator
- STTK 9.59
- TWIN 70.33
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About TWIN Twin Disc Incorporated
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.